Industry gains incentives for drugs for children |
| |
Abstract: | Under the FDA Safety and Innovation Act, manufacturers who get a drug for a rare pediatric disease approved and on the market earn a voucher requiring the FDA to review a second drug within 6 months of submission of an application for its approval. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|